New Zealand markets close in 9 minutes
  • NZX 50

    10,945.17
    +82.83 (+0.76%)
     
  • NZD/USD

    0.6211
    -0.0002 (-0.02%)
     
  • NZD/EUR

    0.5945
    -0.0009 (-0.15%)
     
  • ALL ORDS

    6,822.00
    +25.10 (+0.37%)
     
  • ASX 200

    6,636.00
    +23.40 (+0.35%)
     
  • OIL

    110.36
    +1.93 (+1.78%)
     
  • GOLD

    1,811.90
    +10.40 (+0.58%)
     
  • NASDAQ

    11,585.68
    +81.98 (+0.71%)
     
  • FTSE

    7,232.65
    +64.00 (+0.89%)
     
  • Dow Jones

    31,097.26
    +321.86 (+1.05%)
     
  • DAX

    12,773.38
    -39.65 (-0.31%)
     
  • Hang Seng

    21,955.72
    +125.37 (+0.57%)
     
  • NIKKEI 225

    26,364.81
    +211.00 (+0.81%)
     
  • NZD/JPY

    84.5590
    +0.3200 (+0.38%)
     

Guardant Health to Participate in Upcoming June Investor Conferences

·1-min read

REDWOOD CITY, Calif., May 26, 2022--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.

  • William Blair 42nd Annual Growth Stock Conference in Chicago, IL
    Presentation on Tuesday, June 7th at 11:20 a.m. Central Time

  • Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA
    Fireside Chat on Tuesday, June 14 th at 9:20 a.m. Pacific Time

Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005732/en/

Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michele Rest
press@guardanthealth.com
+1 215-910-2138

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting